Abbott reported Q2 adjusted EPS of $1.31, beating the analyst consensus of $1.28. The company then raised its full-year 2026 earnings guidance to a range of $5.45 to $5.60, with comparable sales growth targeted at 6.5% to 7.5%. Strength in diagnostics and heart devices drove the outperformance.
A guidance raise of this size signals that Abbott's two highest-margin segments are growing faster than Wall Street had modeled. For investors in healthcare ETFs or ABT directly, upward estimate revisions from sell-side analysts typically follow a beat-and-raise quarter, which tends to lift the stock price in the weeks after. Broader medtech names often move in sympathy when a bellwether like Abbott prints strong device numbers.
August earnings season: peer medtech reports from Medtronic (~Aug 19) and Boston Scientific (~Jul 23). Next Abbott investor update at Q3 earnings, expected late October 2025.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block.
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief